The Green Room: A Podcast from Obstetrics & Gynecology October 2024: Obstetrics
Sep 23, 2024
Jennifer Hoskovec, VP of Clinical Affairs at Billion to One, dives into the latest breakthroughs in prenatal testing. She discusses the rise of personalized management for hemolytic disease, emphasizing non-invasive methods and cell-free DNA technology to enhance patient care. The conversation highlights a pivotal study on nipocalumab's potential to treat severe neonatal conditions and introduces innovative algorithms for managing red blood cell isoimmunization. With a focus on collaboration and accuracy, Hoskovec shares insights that could reshape obstetric practices.
AI Snips
Chapters
Transcript
Episode notes
FcRn Blockade Shows Promise
- Nipocalumab blocks the neonatal Fc receptor to inhibit transplacental IgG transfer and reduce severe hemolytic disease risk.
- Early small trials showed fewer intrauterine transfusions and improved live-birth outcomes in high-risk pregnancies.
Comprehensive Clinical Guidance Arrives
- The clinical expert series summarizes prevention, detection, and management of red cell alloimmunization with updated algorithms.
- It emphasizes whole-blood transfusion impacts, emerging therapeutics, and the growing role of cell-free DNA.
Extended Matching Lowers Sensitization
- Extended RBC antigen matching (C, E, K) reduced alloimmunization from 6.2% to 1.9% in pooled studies.
- This supports reconsidering broader matching practices to prevent sensitization.